VentriPoint Diagnostics ( (TSE:VPT) ) has shared an announcement.
Ventripoint Diagnostics has released a whitepaper detailing the advancements of its VMS+™ 4.0 system, which recently received FDA clearance. The new version enhances workflow efficiency and visualization through AI-assisted features, offering a non-invasive, accurate alternative for cardiac imaging. This development positions Ventripoint to provide a fast, affordable diagnostic tool for the global cardiac patient community.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. is a leader in applying AI to echocardiography, offering VMS+™ products powered by proprietary Knowledge Based Reconstruction technology. This technology provides accurate cardiac measurements equivalent to MRI, and is versatile across various ultrasound systems with regulatory approvals in the U.S., Europe, and Canada.
YTD Price Performance: 60.87%
Average Trading Volume: 269,358
Technical Sentiment Signal: Hold
Current Market Cap: C$30.12M
Learn more about VPT stock on TipRanks’ Stock Analysis page.